CF
ELVN icon

Cantor Fitzgerald’s Enliven Therapeutics ELVN Stock Holding History

Cantor Fitzgerald’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-33,088
Closed -$845K – 298
2024
Q3 		$845K Buy
+33,088
New +$766K 0.02% 75

Other funds holding ELVN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

Cantor Fitzgerald's ELVN Position: Q4 2024 in Review

Cantor Fitzgerald sold out of Enliven Therapeutics (ELVN) in Q4 2024, closing a stake of 33,088 shares — an estimated $845K sold.

Cantor Fitzgerald first reported a position in ELVN in Q3 2024 and held it in 1 quarter. The position peaked at $845K in Q3 2024. 113 funds tracked by Wall St. Rank hold ELVN as of Q4 2024.

  • Cantor Fitzgerald reported no remaining Enliven Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Cantor Fitzgerald sold 33,088 Enliven Therapeutics shares in Q4 2024, an estimated $845K.
  • Cantor Fitzgerald first reported a position in Enliven Therapeutics in Q3 2024 and held it in 1 quarter.
  • Cantor Fitzgerald's Enliven Therapeutics position peaked at $845K in Q3 2024.
  • 113 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q4 2024.

Based on Cantor Fitzgerald's 13F filing for Q4 2024, filed 14 Feb 2025.